WHAT IS PEDAL?
In June 2022, LLS launched the PedAL Master Clinical Trial, the first integrated, global, acute leukemia master clinical trial to test new, safer therapies on children, who will be matched to treatments based on their unique tumor biology.
Who is leading the LLS PedAL trial?
LLS is leading an international collaboration, convening some of the best minds in cancer research and treatment. Through partnerships with the National Cancer Institute (NCI) (part of the National Institutes of Health), Children’s Oncology Group (COG), and the European Pediatric Acute Leukemia (EuPAL) Foundation, LLS PedAL is available to children and families in North America, Australia, New Zealand and Europe – bringing the dream of safer, more effective pediatric acute leukemia treatments closer to home for more people.
LLS PedAL is a key component of The Dare to Dream Project, a big, bold campaign to fund groundbreaking pediatric research that will accelerate safer, less toxic and, more effective treatments for kids. We believe it’s not enough that children with blood cancer survive – we want them to have the chance to thrive as survivors.
How does LLS PedAL work?
Through international partnerships, LLS PedAL taps into established infrastructures to make screening and therapeutic trials available to more children.
- The LLS PedAL screening trial identifies the unique tumor biology of each child’s cancer.
- Based on their tumor biology, families can then enroll eligible children in an LLS PedAL therapeutic trial or any other trial that best meets their needs.
- By enrolling their child in the screening trial, parents are helping to advance research for all children because their child’s tumor biology results will be assessed the same way as children’s around the globe to help researchers find patterns and to advance more targeted treatments worldwide.
To learn more about PedAL: https://www.lls.org/dare-to-dream/pedal
